Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target

Seattle Genetics Announced Positive Results for HER2CLIMB Trial
Seattle Genetics (SGEN) announced positive topline results from the HER2CLIMB trial evaluating tucatinib in HER2-positive breast cancer.  The trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine

This content is for paid subscribers.
Please click here to subscribe or here to log in.